Danish Renewable Energy Stock News

Netcompany Group A/S has reported its full-year 2025 results, with sales rising to DKK 7,891.7 million while net income decreased to DKK 256.9 million, leading to lower basic and diluted earnings per share from continuing operations. An interesting contrast for investors is that these earnings were released just after the company completed a DKK 500 million share buyback programme aimed at adjusting its capital structure and supporting share-based incentives. We will now consider how...

H. Lundbeck A/S recently presented six-month real-world data from its 12-month INFUSE study at the 2026 Headache Cooperative of the Pacific Conference in Ojai, California, highlighting outcomes for adults with migraine treated with Vyepti (eptinezumab) after prior preventive anti-CGRP failures. The data showed meaningful improvements in multiple patient-reported outcomes, including an average 6.3 additional "good days" per month, reinforcing the clinical relevance of switching to intravenous...

Genmab (CPSE:GMAB) is back in focus after reporting that worldwide net trade sales of DARZALEX, as disclosed by Johnson & Johnson, reached US$14.351b in 2025. This figure feeds directly into Genmab’s royalty income. See our latest analysis for Genmab. Genmab’s DARZALEX update lands after a strong run in the shares, with a 10.67% 90 day share price return and a 49.98% 1 year total shareholder return. However, the 3 and 5 year total shareholder returns remain negative, suggesting recent...

Jyske Bank has completed its share buyback programme announced in February 2025, repurchasing 5,398,229 shares, or 8.97% of its share capital, for DKK 2,249.99 million by 30 January 2026. Following the programme, Jyske Bank holds 3,309,528 treasury shares, equal to 5.38% of its share capital, underlining management’s clear capital allocation priorities. With this substantial buyback now finished, we’ll explore how such active capital management shapes Jyske Bank’s investment narrative and...

Ambu (CPSE:AMBU B) is back in focus after CEO Britt Meelby Jensen joined a Danish delegation to China and presented a Chinese made endoscope, highlighting a potential shift in the company’s geographic risk profile. See our latest analysis for Ambu. The new China focus comes after a tough run for shareholders, with the share price at DKK84.7 and a 1-year total shareholder return decline of 36%, extending a 5-year total shareholder return drop of 74%. This suggests momentum has been fading...

Danske Bank has completed its DKK 5,000,000,000 share buy-back programme, repurchasing 19,179,623 shares that are expected to be cancelled subject to shareholder approval at the March 26, 2026 annual general meeting. This move underscores a capital position that allows meaningful cash returns to investors and signals management’s confidence in the bank’s current trajectory. We’ll now examine how the completed DKK 5,000,000,000 buy-back and planned share cancellation shape Danske Bank’s...

ALK-Abelló (CPSE:ALK B) is back in focus after regulators in Europe issued a positive opinion on extending EURneffy marketing authorisation to include a 1 mg nasal adrenaline spray for younger children. See our latest analysis for ALK-Abelló. The CHMP opinion appears to have been a fresh catalyst, with ALK-Abelló’s 1-day share price return of 2.12% standing out against a 30-day share price return decline of 6.44%. Its 1-year total shareholder return of 34.35% and 3-year total shareholder...

Novo Nordisk and Aspect Biosystems have moved into a new phase of their diabetes cell-therapy partnership, with Aspect acquiring key stem cell and hypoimmune engineering rights, plus integrated Novo Nordisk R&D and manufacturing capabilities, while Novo Nordisk keeps options to expand its role and earn milestones and royalties on future products. By handing operational leadership of next-generation cell therapies to Aspect while retaining financial and later-stage participation rights, Novo...

Event driven spotlight on Carlsberg stock Carlsberg (CPSE:CARL B) has agreed to sell its 50% stake in Tibet based Lhasa Brewery to Tibet Development, exiting a joint venture that faced management disputes and weaker unit level financial performance. The deal, completing just before Carlsberg’s annual results, removes a contested asset from the portfolio and gives investors fresh context for assessing the group’s earnings profile and capital allocation priorities. See our latest analysis for...

NKT announced that it has signed final contracts under its framework agreement with SSEN Transmission to deliver 525 kV HVDC on- and offshore power cable systems for the Western Isles and Spittal to Peterhead links in Scotland, adding about €2.00 billion to its high-voltage order backlog. Beyond expanding NKT’s backlog, the projects highlight the company’s role in enabling large-scale grid reinforcement for Great Britain’s electricity transmission network. Next, we’ll examine how securing...

Why Ringkjøbing Landbobank is on investors’ radar Ringkjøbing Landbobank (CPSE:RILBA) is drawing attention after a period of solid trailing returns, with the share price up 3.0% over the past month and 7.9% in the past 3 months. Alongside that price performance, the bank reports annual revenue of DKK 4,125.703 and net income of DKK 2,283.784. These figures give investors concrete numbers to weigh against its recent share price moves. See our latest analysis for Ringkjøbing Landbobank. At a...

As the eurozone economy continues its modest recovery, with consumer and business confidence on the rise despite mixed performances in major stock indexes, investors are keenly observing growth companies that demonstrate strong insider ownership. In this context, stocks with high insider ownership can be particularly appealing as they often reflect a management team’s confidence in their company’s long-term potential and alignment with shareholder interests.

Recently, Ambu’s CEO Britt Meelby Jensen joined a Danish life science delegation to China, presenting a new Chinese-made endoscope as part of efforts to deepen cooperation and diversify the company’s global value chain away from a more difficult US market. This move highlights how Ambu is reconfiguring its manufacturing and market exposure to tap Chinese healthcare demand while reducing reliance on a single geography. We’ll now examine how Ambu’s increased focus on Chinese manufacturing and...

Key Insights The considerable ownership by individual investors in TORM indicates that they collectively have a greater...

In late January 2026, Aktieselskabet Schouw & Co. issued consolidated revenue guidance for 2026, forecasting between DKK 33,000 million and DKK 35,500 million. This guidance provides investors with a clearer view of the company’s expected scale of operations and potential demand across its portfolio businesses. We’ll now examine how this 2026 revenue outlook sharpens Aktieselskabet Schouw’s investment narrative and what it may imply for future positioning. Trump has pledged to "unleash"...

Why NKT’s new Scottish HVDC contracts matter for investors NKT (CPSE:NKT) has secured final contracts with SSEN Transmission for two Scottish HVDC links, a turnkey package covering design, production and installation of 525 kV cable systems worth about €2b. The projects, Western Isles and Spittal to Peterhead, are now part of NKT’s high voltage order backlog, with contract values reflecting higher raw material costs and the inclusion of full cable installation scope. See our latest analysis...

Novo Nordisk (CPSE:NOVO B) is back in focus after the US launch of its oral Wegovy pill, where early prescription data suggest a strong start that many investors view as a potential turning point. See our latest analysis for Novo Nordisk. The early strength of the Wegovy pill launch comes after a tough stretch, with Novo Nordisk reporting a 1-year total shareholder return decline of 37.4%, even as the 90-day share price return sits at 17% and the 5-year total shareholder return remains up...

INFUSE study data puts Vyepti in focus for Lundbeck investors H. Lundbeck (CPSE:HLUN B) has drawn investor attention after presenting six month real world INFUSE study data on its migraine treatment Vyepti at the 2026 Headache Cooperative of the Pacific conference. See our latest analysis for H. Lundbeck. The INFUSE update lands after a mixed stretch for the shares, with a 1-day share price return of 1.06% to DKK42.12 contrasting with weaker 7-day, 90-day and 1-year total shareholder return...

DSV recently broke ground on a new US$14.5 million, 88,258‑square‑meter regional headquarters and logistics facility in Mesa, Arizona, which will consolidate air, sea, road, and contract logistics services and ultimately employ about 160–200 people. By positioning this hub near Phoenix‑Mesa Gateway Airport to support sectors such as semiconductors and advanced manufacturing, DSV is tying its growth plans to Arizona’s expanding high‑tech supply chain ecosystem. We will now examine how this...

Share buy-back puts Rockwool (CPSE:ROCK B) in focus Rockwool (CPSE:ROCK B) has moved into the spotlight after launching a share buy-back programme of up to €150m. Recent disclosures show 4,786,356 B shares held, equal to 2.26% of share capital. See our latest analysis for Rockwool. The new buy-back comes against a softer share price backdrop, with a 30-day share price return showing a 5.26% decline and a 1-year total shareholder return showing a 14.64% decline. The 3-year total shareholder...

Vattenfall has ordered Vestas turbines featuring low-emissions steel for the 63 MW Clashindarroch II wind farm in Scotland, marking the first time this lower-impact material has been used in a commercial wind project. This step highlights how Vestas is integrating cleaner materials into turbine manufacturing, potentially reshaping sustainability standards across the wind supply chain. We’ll now explore how this pioneering use of low-emissions steel could influence Vestas’ investment...

ISS has announced that it previously secured a three-year Integrated Facility Services contract, worth close to DKK 300 million annually, to become the primary facilities partner for a major life sciences and pharmaceutical company across four Swiss locations starting in the second quarter of 2026. By moving from a subcontractor role to direct ownership of a wide range of technical, cleaning, logistics and laboratory services under one integrated FM setup, ISS is deepening its position in a...

Novo Nordisk (CPSE:NOVO B) and Aspect Biosystems are moving into a new phase of their collaboration to develop advanced cellular medicines for diabetes. The partners are working on cell-based therapies that target disease modification or potentially curative treatment options. The program focuses on islet replacement therapy for type 1 diabetes that is designed to function without chronic immune suppression. For readers who mostly associate Novo Nordisk with obesity treatments like Wegovy,...

RTX (CPSE:RTX) Q1 2026 earnings snapshot RTX (CPSE:RTX) opened its 2026 financial year with Q1 revenue of DKK115.9 million, a basic EPS loss of DKK1, and net income excluding extra items at a loss of DKK8.3 million. This sets a cautious tone around profitability to start the year. Over the prior year, quarterly revenue has moved between DKK104.0 million in Q1 2025 and DKK165.5 million in Q2 2025. Basic EPS ranged from a loss of DKK0.90 in Q1 2025 to a high of DKK0.99 in Q2 2025, highlighting...